Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER

Ortega‐Castro, Rafaela; Font‐Ugalde, Pilar; Castro-Villegas, M.C.; Calvo‐Gutiérrez, Jerusalem; Gomariz, E. Muñoz; Montejo, Pedro Zarco; Almodóvar, Raquel; Mendoza, Juan Mulero; Torre-Alonso, Juan Carlos; Masmitjá, Jordi Gratacós; Roura, Xavier; Ariza, Rafael Ariza; Dapica, Pilar Fernández; Ferrando, Luis Francisco Linares; Brito, MJ; Quintana, Eduardo Cuende; Galeano, Carlos Vázquez; Ramos, Manuel José Moreno; Úbeda, Eugenio Giménez; Lozano, José Carlos Rodríguez; Prada, Manuel Fernández; Queiró, Rubén; Ruzafa, Estefania Moreno; Navarro, Enrique Júdez; Más, Antonio Juan; Quement, Cristina Medrano Le; Ornilla, Enrique; Morales, Carlos; Busquets, Manuel Pujol; Clavaguera, Teresa; Fernández-Espartero, María Cruz; Carmona, Loreto; Estévez, E. Collantes

doi:10.1016/j.reuma.2012.09.008

Cited by 21 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, women referred higher involvement of peripheral joints, dactylitis and enthesitis, associated with higher disease activity (BASDAI) and worse quality of life (ASQoL). Similar data were observed in 1505 patients from the Brazilian Registry of Spondyloarthritis (RBE) [26] and 1514 patients from the Spanish SpA Registry (REGISPONSER), [27] as well as in a British study [28] and in the French DESIR cohort, which included patients with axial SpA of recent onset. [29] …”

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort

et al. 2016

View full text Add to dashboard Cite

The aim of the study was to compare clinical manifestations, disease activity, functional capacity, spinal mobility, and radiological findings between men and women from a multicenter, multiethnic Ibero-American cohort of patients with Spondyloarthritis (SpA).This observational cross-section study included 1264 consecutive SpA patients who fulfilled the modified New York criteria for ankylosing spondylitis (AS). Demographic, clinical, and radiologic data were evaluated. Categorical data were compared by X2 or Fisher's exact tests and continuous variables by ANOVA with post-hoc tests.Primary AS was diagnosed in 1072 patients, psoriatic spondylitis in 147, and spondylitis associated to inflammatory bowel disease (IBD) in 45 patients. Overall, male patients were significantly younger, had longer diagnostic delay, lower disease activity, worse spinal mobility, better quality of life, and more severe radiologic damage. Dactylitis and enthesitis, as well as swollen joint count, were significantly more common among women. In primary AS, there was a marked male predominance (76.2%). Among patients with psoriatic spondylitis, male predominance was lower (57.8%), but was also associated with worse spinal mobility and more severe radiologic damage. In the total population, male patients with primary AS referred higher permanent work disability (13.2% vs 6.9%; P < 0.05), although no difference was observed in psoriatic or IBD spondylitis according to the gender.Among Ibero-American SpA patients, there are some differences in clinical and radiological manifestations, men showing more structural damage, whereas women more active disease. These data suggest that the phenotype of SpA differs between genders. This can influence the subsequent diagnostic approach and therapeutic decisions.

show abstract

Section: Discussionsupporting

confidence: 69%

“…[27,30,31] However, some factors should be taken into consideration. First, family history of SpA was not analyzed, having been shown that its presence is associated with lower delay, and second, in this cohort women presented worse disease activity (BASDAI) and quality of life (ASQoL), which may have driven in a prompt medical consultation.…”

Section: Discussionmentioning

confidence: 99%

Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The proportion of female patients was significantly lower among the group of patients who progressed from nr-axSpA to AS [ 8 ]. The female predominance of patients with nr-axSpA can be understood in the same context, as male patients with AS have more severe radiographic damage than female patients with AS [ 1 , 9 ]. The underlying pathogenesis of the differences between men and women with AS is still unknown.…”

Section: Introductionmentioning

confidence: 99%

Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model

et al. 2017

View full text Add to dashboard Cite

BackgroundAnkylosing spondylitis (AS) is a male-predominant disease, and radiographic evidence of damage is also more severe in males. Estrogen modulates immune-related processes such as T cell differentiation and cytokine production. This study aimed to evaluate the effect of estrogen on the disease activity of spondyloarthritis (SpA).MethodsThe effects of estrogen on the development of arthritis were evaluated by performing ovariectomy and 17β-estradiol (E2) pellet implantation in zymosan-treated SKG mice. Clinical arthritis scores were measured, and 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography performed to quantify joint inflammation. The expression of inflammatory cytokines in joint tissue was measured.ResultsE2-treated mice showed remarkable suppression of arthritis clinically and little infiltration of inflammatory cells in the Achilles tendon and intervertebral disc. 18F-FDG uptake was significantly lower in E2-treated mice than in sham-operated (sham) and ovariectomized mice. Expression of TNF, interferon-γ, and IL-17A was significantly reduced in E2-treated mice, whereas expression of sclerostin and Dickkopf-1 was increased in E2-treated mice compared with sham and ovariectomized mice.ConclusionsEstrogen suppressed arthritis development in SKG mice, a model of SpA. Results of this study suggest that estrogen has an anti-inflammatory effect on the spondyloarthritis manifestations of the SKG arthritis model.

show abstract

“…Ankylosing spondylitis (AS) is a male-predominant disease and male gender is associated with more severe radiographic progression 1 , 2 . Male patients progressed from non-radiographic axial spondyloarthritis (SpA) to AS more frequently than female patients 3 .…”

Section: Introductionmentioning

confidence: 99%

Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice

Jeong

Kim

Bae

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Ankylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.

show abstract

Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER

Cited by 21 publications

References 9 publications

Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort

Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort

Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model

Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice

Contact Info

Product

Resources

About